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Abstract: Cell penetrating peptides (CPP) or membrane translocating peptides such as, 
penetratin from Antennapedia homeodomain or TAT from human immunodeficiency virus are 
useful vectors for the delivery of protein antigens or their cytotoxic (Tc) or helper (Th) T cell 
epitopes to antigen presenting cells. Mice immunized with CPP containing immunogens elicit 
antigen-specific Tc and/or Th responses and could be protected from tumor challenges. In the 
present paper, we investigate the mechanism of class I and class II antigen presentation of 
ovalbumin covalently linked to penetratin (AntpOVA) by bone marrow-derived dendritic cells 
(BMDC) with the use of  biochemical inhibitors of various pathways of antigen processing and 
presentation. Results from our study suggested that uptake of AntpOVA is via a combination of 
energy independent (membrane fusion) and energy dependent pathways (endocytosis). Once 
internalized by either mechanism, multiple tap-dependent or independent antigen presentation 
pathways are accessed whilst not completely dependent on proteasomal processing but involving 
proteolytic trimming in the ER and Golgi compartments. Our study provides an understanding on 
the mechanism of antigen presentation mediated by CPP and leads to greater insights into future 
development of vaccine formulations. 
Keywords: Antennapedia; cell penetrating peptides; Antp; vaccine; membrane 
translocating peptide; CPP; cytotoxic T cell epitope; ovalbumin; TAT. 
Introduction 
There are many challenges confronting vaccine development for cancer. These include 
immunosuppression by the tumor microenvironment, identification of appropriate tumor associated 
antigens (TAA), efficient delivery of vaccine antigen and maintenance of immune responses[1]. It is 
accepted that vaccines must efficiently target antigen presenting cells (APC), provide a strong adjuvant 
to break tolerance, utilize multiple TAA that are widely expressed and result both in priming of 
functional CD4 and CD8 T cells and the induction of tumor-specific antibodies (Ab)[2].  
Dendritic cells (DC) are the major APC involved in generating immune responses to cancer 
antigens. Studies have identified receptors on various DC subtypes that are efficient in generating 
immune responses[3,4]. There are also multiple approaches reported for the targeted delivery of 
antigens to some of these receptors expressed on DC and few vaccines are currently in clinical trials[4-
8]. 
Cell penetrating (CPP) or membrane translocating peptides (MTP) are a group of cationic peptides 
that have the ability to spontaneously enter the cytoplasm of cells[9-12]. These peptides have been 
used to deliver a number of cargos such as proteins, peptides, DNA, RNA, drugs and virus particles 
into cells. For these purposes 2 CPP, TAT from the human immunodeficiency virus transactivator of 
transcription protein and penetratin from the Drosophila Antennapedia domain have been used 
extensively[13].  The Drosophila Antennapedia DNA binding domain contains 60 amino acids and 
consists of 3 α-helices, with internalizing activity mapped to a 16 amino acid peptide, penetratin 
(RQIKIWFQNRRMKWKK; Antp) within the third helix.   
The cell penetrating property of these peptides have been used to deliver antigenic peptide and 
proteins into antigen presenting cells including DCs for the development of vaccine delivery 
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systems[13-28]. For this purpose peptides chemically conjugated to protein antigens or synthetic 
peptides of CPP fused in tandem with cytotoxic (Tc) or helper (Th) T cell epitopes have been used. 
Mice immunized with these constructs generated antigen-specific CD4, CD8 or mixed responses and 
were protected from a tumor challenge. Several studies have investigated the immunogenicity of 
recombinant fusions of antigenic proteins with the TAT CPP either alone or with DC. DC based 
vaccines have been successfully tested in animal models and some have been tested in human clinical 
trials, however, the need for leukopheresis and processing leading to extensive costing prevents 
widespread utility in the clinic[29]. 
The uptake of CPP has been studied extensively however the mechanism is controversial. This is 
mainly due to the specific mode of uptake being dependent on the particular CPP, cell type, attached 
cargo or concentration[9,10,28]. Thus, in the context of CPP in vaccine delivery the mechanism will be 
dependent if TAT or penetratin is used or if a peptide or protein cargo is used. In addition, uptake in 
DC will also be different to other cell types. Pouniotis et al. previously reported the uptake and antigen 
presentation of tandem Antp CPP fused with a Tc cell epitope by murine DC[20]. These studies 
demonstrated that the peptides were endocytozed via phagocytosis or micropinocytosis in an energy 
dependent manner and is processed by a proteasome- and tapasin-independent pathway for CD8 
epitope presentation. This mechanism for Antp based peptide immunogens was different to TAT based 
peptide immunogens in that they were tapasin independent but required further processing in trans-
Golgi and ER compartments[30]. In addition, immunogenicity studies in mice with penetratin 
covalently linked to ovalbumin and tandem linked to OVA CD4 and/or CD8 epitopes demonstrated 
OVA-specific class I and class II responses resulting in prophylactic and therapeutic protection of mice 
from a tumor challenge[21].  
The mechanism of Antp linked antigens have not been studied previously and in the current study 
we investigate the uptake, processing and presentation of AntpOVA in bone marrow-derived DC 
(BMDC) utilizing a number of biochemical inhibitors of the various pathways. Using the B3Z OVA-
specific mouse T cell hybridoma, T cells from OT-I and OT-II mice as readouts of T cell activation we 
demonstrate that AntpOVA is internalized by a combination of energy dependent endocytotic process 
and energy independent direct translocation into the cytosol. Once internalized OVA can be processed 
by multiple tap-dependent or independent pathways with proteasomal or ER/Golgi-mediated 
proteolytic trimming for Class I presentation. 
 
Experimental Section 
Peptides and proteins 
SIINFEKL OVA257-264 H-2K
b CD8 T cell epitope (OVA CD8) and OVA323-339 16-mer IA
b CD4 T 
cell epitope (ISQAVHAAHAEINEAGR, OVA CD4) from ovalbumin were used in the study. 
Penetratin (Antp) is the 16 amino acid peptide (RQIKIWFQNRRMKWKK) from Antennapedia. All 
peptides were synthesized by GenScript Corporation (USA) and the purity of the peptides (>95%) was 
determined by high performance liquid chromatography (HPLC) and mass spectrometry. Ovalbumin 
protein (OVA) was purchased from Sigma (A2512, VIC, Australia) and endotoxin removed by 
treatment with triton-X114[31].  
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Conjugation of penetratin to ovalbumin 
Penetratin was conjugated to OVA as described previously[21]. Briefly, OVA [3-5 mg/ml, 
minimally glycosylated (A2512, Sigma)] in phosphate buffered saline (PBS) was reacted with 
sulfosuccinimidyl 4-maleimidomethylcyclohexane carboxylate (SMCC), and then reacted with a C-
terminal cysteine-modified penetratin. The thioether linked penetratin-OVA (AntpOVA) was dialyzed 
in PBS and stored at –20oC. 
 
Dendritic cell cultures  
Bone marrow cells from C57BL/6 female or TAP-/- mice were cultured at 106 cells/ml. Petri dishes 
containing 10 ml of complete RPMI 1640 media [RPMI-1640 media supplemented with 10% (v/v) 
heat inactivated foetal calf serum (FCS), 4 mM L-glutamine, 100 units/ml penicillin, 100 μg/ml 
streptomycin sulphate and 100 μM -mercaptoethanol] (CSL, Australia) with 10 ng/ml of GM-CSF 
and 10 ng/ml of IL-4. At day 6, cells express medium-high levels of CD11c, CD40, CD80 and CD86 
and are characteristic of semi-mature DCs and are approximately 80% CD11c+, MHC class II (not 
shown). DCs were flushed from each dish and washed. DCs were used to assess the kinetics of uptake 
of AntpOVA by flow cytometry and for pulsing with AntpOVA for 3 hours (h) at 37oC, for all 
mechanistic studies. 
 
Kinetics of AntpOVA uptake  
C57BL/6 bone-marrow derived DC (0.5x106 cells in 1 ml media - 10% (v/v) fetal calf serum 
(FCS)/RPMI 1640) were used. (i) Kinetics of uptake was assessed by adding AntpOVA or OVA alone 
at various times (5-120 minutes (min)) at fixed concentration (100 g/ml) at 37°C. Kinetics of uptake 
was also assessed by the addition of AntpOVA or OVA alone for a fixed time (60 min) at varying 
concentrations (10-200 g/ml). Uptake of antigen was assessed by flow cytometry and % uptake of 
total live cells is shown[28]. After incubation, the cells were washed twice with 0.5% (w/v) BSA/PBS, 
fixed with 2% paraformaldehyde (10 min) and washed again with 0.5% (w/v) bovine serum albumin 
(BSA)/PBS. The cells were then permeabilized with 0.5% (w/v) Saponin/PBS for 10 min and anti-
OVA polyclonal antibody(diluted in saponin/PBS) were added for 45 min at 4°C. After washing the 
cells with Saponin/PBS 1:50 -FITC-anti-mouse anti-F(ab’)2 in Saponin/PBS was added for a further 45 
min at 4°C. Finally, cells were washed twice with 0.5% BSA/PBS. DC were resuspended in PBS and 
transferred in FACS tubes and analyzed using flow cytometry. Uptake of OVA was calculated by 
measuring the % surface  (non-permeabilised) and % intracellularly stained cells (permeabilised) with 
results expressed as % uptake = % intracellular-% surface. 
 
Mice and immunizations 
C57BL/6 mice were bred and housed at the Biological Research Laboratory at the Austin Research 
Institute, Heidelberg, Australia. Groups of 4 C57BL/6 mice were immunized either twice (days 0, 14) 
with either AntpOVA or OVA intradermally at the base of the tail either alone (20 g per mouse in 50 
µl) or with DC pulsed with OVA or AntpOVA (20 g/ml) (1x106 pulsed DC/mouse).  
 
Immunological assays 
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ELISpot 
Spleen cells from immunized C57BL/6 mice were isolated 14 days after the last injection and 
assessed by ELISpot for IFN- secretion. Mixed acetate plates (MAIP Millipore) were coated 
overnight with anti-mouse IFN- (AN18, 5 g/ml, Mabtech Germany). 0.5x106 spleen cells/well were 
added and incubated in 10% FCS RPMI 1640 media in the presence (20 g/ml) of OVA, CD4 epitope 
or SIINFEKL for at least 18 h. ConA (1 g/ml) or cells alone were used as positive and negative 
controls, respectively. Cells were discarded and after washing (0.05%Tween 20/PBS) anti-mouse IFN-
 antibody-biotin (R4-6A2, Mabtech, CA, USA) was added for 2 h followed by extravidin-alkaline 
phosphatase (AP) at 0.1 g/ml (Sigma, UK) for 2 h at room temperature. Spots of activity were 
detected using a colorimetric AP kit (Biorad, Hercules, CA, USA). Cytokine spots were counted with 
an AID ELISpot reader system (Autoimmun Diagnostika GmbH, Germany). Data are presented as 
mean spot forming units (SFU) per 0.5x106 cells +/- standard deviation of the mean (SD).  
 
Stimulation of LacZ inducible ovalbumin-specific T cell hybrid 
The B3Z T cell hydridoma line contains a gene construct of E.coli LacZ reporter gene linked to the 
nuclear factor of activated T cells (NFAT). Recognition of OVA-Kb peptide in the context of MHC 
class I by the TCR results in activation of the enzyme and conversion of the chromogenic substrate that 
can be measured by absorbance spectrophotometry[32]. DC (106 cells) were pulsed with different 
concentrations of AntpOVA, OVA (20, 50, 100, 200 g/ml) or SIINFEKL (1, 10 g/ml) for 24 h. DC 
(2x105) were added to 105 B3Z cells in 96 well microtitre plates. Following overnight incubation at 
37oC, cells were washed with sterile PBS and incubated with chlorophenol red -D-galactopyranoside 
(Calbiochem, San Diego, CA) for a further 4 h and optical density was measured at 560 nm using a 
microplate reader. 
 
Antigen-specific T cell responses in vitro 
Purified T cells were obtained from OT-I and OT-II mice using a T cell cocktail (kindly provided 
by Dr. Mark Wright, Department of Immunology, Monash University). The purity of the population 
was greater than 85% as identified by CD3 staining by flow cytometry (data not shown).  T cells were 
co-cultured in 96-well plates in the presence or absence of pulsed DC. DC were pulsed with AntpOVA 
(100 g/ml), SIINFEKL (1 g/ml), OVA CD4 or ovalbumin (100 g/ml) for 24 h. The co-cultures 
comprised of 2x105 T cells and 2x104 DC in a total volume of 200 l. Proliferative responses were 
assessed from day 1 to day 6 of culture at 37oC. Cultures were pulsed with 1 µCi [3H]-thymidine for 18 
h, and incorporation of the radionucleotide was measured by -scintillation spectroscopy using 
TopCount Gamma Counter (Packard, USA). 
 
Mechanism Studies 
 
MHC class I pathway 
The effects of MHC class I processing and presentation of AntpOVA by DC was evaluated by the 
B3Z.IG7 T cell hybridoma assay[20,32]. DC, EL4 (TAP-competent) and RMA-S (TAP-deficient) cells 
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were cultured in 10% FCS/RPMI media. Cells were added to 24 well plates (Falcon, BD Biosciences) 
at 6x105/300 l and pre-incubated for 45 min with various inhibitors. NaN3 (0.01-10 mM) (Sigma, 
USA) and 2-deoxyglucose (0.01-10 mM) (Sigma, USA) deplete cellular ATP activity and energy-
dependent processes within cells. Disruption of membrane activities was induced by amiloride (0.006-
6 mM) (Sigma, USA) which inhibits membrane cycling and macropinocytosis, cytochalasin D (0.01-
10 g/ml) (Sigma, USA) which blocks phagocytosis and dextran sulphate (Progen Industries Ltd, 
Australia) (0.01-10 g/ml) which interacts with the positive charges of penetratin and thereby blocks 
interaction of penetratin with negative charge on the surface of cellular membranes. Nystatin (0.5, 5, 
50 µg/ml) inhibits caveola-dependent endocytosis and filipin III (1, 5, 10 g/ml) is a cholesterol 
depleting agent used to inhibit lipid raft associated endocytosis. Processing via endocytosis was 
inhibited by chloroquine (0.2-200 M) (Sigma, USA), ammonium chloride, NH4Cl (0.2-200 M) 
(Ajax Chemicals, Australia) and monensin (1-1000 M) (Sigma, USA) which all interfere with 
acidification of endosomal pH vesicles from early to late endosomes and lysosomes. Proteasomal 
activity was inhibited by lactacystin (0.01-10 M) (Calbiochem, USA). Protein transport from 
endoplasmic reticulum (ER) to the golgi complex was blocked by brefeldin (0.01-10 g/ml) (Sigma, 
USA), furin inhibitor decRVKR-CMK (0.01-10 M) (Calbiochem, USA) inhibits endopeptidase 
activity via the trans-golgi and bestatin (0.01-10 M) (Sigma, USA) inhibits aminopeptidase activity in 
the ER. After the pre-incubation period, AntpOVA was added to cells at 100 g/ml for 3 h at 37oC and 
cells were added to B3Z.IG7 cells as described above. The inhibitors were active and concentrations 
used were non-toxic[15,20,33]. In all experiments, DC pulsed with OVA CD8 (SIINFEKL) or OVA 
CD4 (ISQAVHAAHAEINEAGR) in the presence or absence of biochemical inhibitor demonstrated 
that the inhibitor did not have any effects on the T cells (not shown). 
 
MHC class II pathway  
The effects of MHC class II processing and presentation was evaluated by intracellular IFN- 
production by purified OT-II transgenic splenocytes. DC were pre-incubated for 45 min with similar 
inhibitors described for MHC class I mechanism studies. DC were then incubated for 3 h at 37oC at 
5x105/500 l with 100 g/ml of AntpOVA. The next day, purified OT-II T cells (purification method 
described above) were added at 106/500 l to each of the DC culture conditions and incubated at 37oC 
for 2 h. Three hours before the incubation period was completed, 1 g/ml of brefeldin was added to the 
cultures. The ability of DC presenting AntpOVA to MHC class II restricted OT-II T cells was assessed 
by intracellular IFN- secretion co-stained with CD3. Additional control conditions were also set up to 
include DC pulsed with SIINFEKL (20 g/ml), OVA323-339 (20 g/ml) or no peptide. For intracellular 
IFN- staining, DC were washed twice with 0.5% (v/v) BSA/PBS and stained with anti-CD3 
(Pharmingen, BD, USA) for 45 min on ice, washed twice with 0.5% BSA/PBS then fixed with 2% 
(w/v) paraformaldehyde for 10 min and washed again with 0.5% BSA/PBS. Cells were permeabilized 
with 0.5% (w/v) saponin/PBS for 10 min. Anti-IFN- (Pharmingen, BD, USA) was added for 45 min 
on ice, cells were washed twice with 0.5% (w/v) saponin/PBS. After resuspending the cells in PBS, 
they were transferred into FACS tubes and were immediately analyzed using flow cytometry. Data was 
analyzed using CellQuest software.   
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Confocal microscopy studies 
AntpOVA was labelled with Alexa Fluro 488 N-hydroxysuccinimide ester as described in 
manufacturer’s instructions (Molecular Probes, Eugene, OR, USA). BMDC (5x104 cells) were seeded 
in eight well chamber slides overnight at 37ºC. The next day culture media was aspirated and replaced 
with 200 µl Hank's Buffered Salt Solution (HBSS) and pulsed with Alexa-labelled AntpOVA for 2 h 
37ºC. Hoechst nuclear stain (10 µg/ml) was added for 15 min at 37ºC. Cells were washed extensively 
and visualized using a laser scanning confocal microscope. To prevent fixation artefacts all 
measurements of peptide uptake were performed with living, non-fixed cells.  
 
Statistical analysis 
Assays were set up in triplicate. Mean values were compared using an unpaired t-test, one-way 
analysis of variance or Kruskal–Wallis analysis of variance using Dunn’s test for multiple 
comparisons. Three p value thresholds are noted in the text, p<0.001 (***) to indicate a extremely 
significant difference, p<0.01 (**) to indicate very significant and p<0.05 (*) to indicate a significant 
difference. 
 
Results 
 
Uptake of AntpOVA by DCs 
To analyze the uptake of AntpOVA by APCs, in vitro grown DCs (> 80% CD11c+) were incubated 
with titrating concentrations of AntpOVA and compared to OVA alone. DCs were pulsed for 60 min 
with 10, 20, 50, 100 and 200 g/ml of AntpOVA compared to OVA alone (Figure 1A). A polyclonal 
rabbit anti-mouse OVA was used to detect intracellular OVA in permeabilized DC. Uptake of 
AntpOVA at all concentrations; 100 g/ml (42±3%), 50 g/ml (33±5%) and 20 g/ml (23±4%) were 
significantly above (p<0.001) uptake of OVA pulsed DC (Figure 1A). Since the uptake of AntpOVA 
was very efficient in DCs, we set up a time course assay to assess the kinetics of AntpOVA 
internalization into DCs.  DCs were pulsed with 100 g/ml of AntpOVA or soluble OVA 
(concentration chosen as it showed the optimal uptake in concentration experiments in Figure 1A) for 
5, 15, 30, 60 and 120 minutes (mins) at 37oC (Figure 1B). Intracellular OVA in AntpOVA pulsed DC 
was detected at all time points at similar levels and at significantly greater levels than in OVA-pulsed 
DC, which emphasized how efficiently penetratin can transport whole protein into DCs.  
The uptake of AntpOVA by DCs was also visualized by confocal microscopy. Alexa 488-labelled 
AntpOVA was rapidly taken up by DC with accumulation in vacuolar compartments and cytosol 
(Figure 1C & D). 
8 
 
 
 
Figure 1. Uptake and presentation of AntpOVA by dendritic cells. (A) DC were 
incubated for 60 min with titrating concentrations of OVA (■) or AntpOVA (●) at 10, 20, 
50, 100 and 200 µg/ml or (B) DC were incubated with 100 µg/ml OVA (■) or AntpOVA 
(●) for 5, 15, 30, 60 and 120 min intervals. Cells were fixed, permeabilized and stained 
with a polyclonal rabbit anti-OVA followed by FITC-labelled F(ab’)2 anti-rabbit antibody 
and examined by intracellular flow cytometry analysis. Data is shown as mean±SEM of 2 
independent experiments. (C) Confocal imaging of uptake of Alexa Fluor 488-labelled 
AntpOVA by DC. DCs were incubated with Alexa-labelled AntpOVA (green) in chamber 
slides for 2 hr, counterstained with Hoechst nuclear stain (blue), washed and visualized by 
confocal microscopy. (D) Control DC stained with Hoechst nuclear stain only. 
AntpOVA can stimulate antigen-specific CD8+ and CD4+ T cell responses in vivo 
We further evaluated the potential of AntpOVA to induce CD8+ and CD4+ T cell responses in vivo 
[21]. Groups of 4 C57BL/6 mice were immunized with 25 g soluble OVA, 25 µg AntpOVA,DCs 
pulsed with soluble OVA at 20 µg/ml or DCs pulsed with AntpOVA at 20 g/ml.  All mice were given 
2 intradermal (base of tail) injections, 14 days part. Sixteen days after the final injection, spleens were 
removed from mice and antigen-specific IFN- responses were detected via ELISpot assay. Mice 
immunized with AntpOVA showed highly significant IFN- responses to SIINFEKL, OVA CD4 and 
to a lesser extent, whole OVA compared to control mice (Figure 2A). There were no increase in IFN- 
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responses, although some OVA323-339-specific responses were detected in OVA immunized mice 
compared to controls (Figure 2B). In comparison, mice that were immunized with DCs pulsed with 
AntpOVA showed high IFN- responses specific to SIINFEKL, OVA323-339 and whole OVA but not as 
high as AntpOVA alone (Figure 2C). Similar IFN- responses were achieved after immunization with 
DCs pulsed with soluble OVA as seen with soluble OVA alone (Figure 2B & D). Comparing mice that 
were immunized with or without DCs, the results show that after 2 immunizations, mice immunized 
with AntpOVA alone gave significantly higher IFN- responses (p<0.05) via both MHC class I and II 
to stimulate potent CD8+ and CD4+ T cell responses. Moreover, both groups of mice immunized with 
AntOVA with or without DC showed significantly higher IFN- responses than the corresponding 
OVA and OVA+DC treated groups (p<0.05).These results suggest that using penetratin conjugated to 
protein is immunogenic without the need for ex-vivo pulsing of DCs. 
  
Figure 2. CD8+ and CD4+ antigen-specific IFN- responses induced by AntpOVA. 
Groups of 4 C57BL/6 mice were immunized with (A) AntpOVA (B) OVA at 25 µg per 
mouse or with DCs pulsed with (C) DC+AntpOVA, or (E) DC+OVA at 20 µg/ml. 
Immunizations were given twice, 14 days apart, intradermally at the base of the tail. 
Sixteen days post-immunization mice were killed and spleens removed and IFN- 
responses using recall antigens (control, SIINFEKL, OVA CD4 peptide or ovalbumin) 
were assessed via ELISpot assay. Results are shown as spot forming (SFU) per 0.5 million 
cells. Data is shown as mean±SD from three replicate wells from 4 mice and representative 
of 2 independent experiments. One-way analysis of variance (ANOVA) was performed 
and ***, p<0.001; **, p<0.01; *, p<0.05; ns, not significant. 
Mechanism of AntpOVA antigen presentation 
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To study the mechanism of processing and presentation of ovalbumin delivered via penetratin we 
utilized various inhibitors of MHC class I and class II intracellular trafficking and processing 
pathways. To demonstrate processing and presentation we utilized 2 assays; (i) the stimulation 
(proliferation or intracellular IFN- secretion) of purified CD8+ and CD4+ T cells from T cell receptor 
(TCR)-transgenic OT-1 and OT-II mice, and, (ii) the stimulation of B3Z T cell hybridoma by 
AntpOVA pulsed bone marrow derived DCs.  
 
AntpOVA is processed and presented via a TAP independent pathway.  
It has previously been shown that the activation of OT-I T cells by AntpSIIN peptide pulsed DC 
occurs in a TAP-independent manner[20]. To ascertain if the processing and presentation of AntpOVA 
is TAP dependent, bone marrow derived DC from TAP1-/- [34,35]and wild type C57BL/6 mice were 
pulsed with AntpOVA, OVA or SIINFEKL were used for stimulation of purified OT-1 T cells.  Both 
TAP1-/- and wild type DCs were able to stimulate the OT-1 T cells (Figure 3A and B). This was further 
confirmed when similar results were obtained when pulsed TAP1-/- and wild type DC or RMA-S 
(TAP-/-) and EL-4 cells were used to stimulate the B3Z T cell hybridoma (not shown).  
  
Figure 3. Tap independent MHC class I processing pathway. In vitro grown (A) 
C57BL/6 and (B) TAP1-/- DCs were pulsed with AntpOVA, SIINFEKL, AntpSIIN and 
CD4 epitope (343-359) at 20 µg/ml for 24 h then added to purified OT-I T cells and 
cultured for 5 days. Cells were harvested at each time point and [3H]-thymidine was 
measured to assess T cell proliferation. OT-I T cells, DC alone and DCs plus T cells were 
used in experiments as negative controls. Data presented as mean counts per minute (cpm) 
±SD from quadruplicate wells and representative of 2 independent experiments. 
Uptake of AntpOVA.  
Membrane translocating peptides such as penetratin and TAT are known to translocate to the 
cytosol of cells by forming inverted micelles[36].  It is now becoming apparent that the uptake could 
also be via endocytosis[12,37].  To ascertain the mechanism of OVA presentation we have used 
various inhibitors that can prevent uptake and thereby interfering with the processing and presentation 
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of AntpOVA by DC. Use of sodium azide (NaN3)/2-deoxyglucose known to inhibit cell membrane 
activities as well as cellular ATP dependent processes, resulted in 62±5% reduced stimulation of B3Z 
cells (Figure 4A)[38]. Cytochalasin D an agent that disrupts cellular actin organization also inhibited 
the presentation of AntpOVA to B3Z cells by 56±6% suggesting that uptake is dependent on an 
endocytic process (Figure 4B)[39,40].  Studies have indicated that the Antp peptides due to their 
cationic nature binds to negatively charged receptors and enter the cell by an endocytic process.  
Dextran sulphate a negatively charged polysaccharide inhibited uptake by 56±2% probably by 
preventing receptor binding by competition (Figure 4C)[41,42].  The uptake of AntpOVA was 
independent of caveolae as 2 inhibitors of this process, filipin III and nystatin had no effect (Figure 4D, 
4E)[43-45]. 
  
Figure 4. AntpOVA internalizes via energy-dependent, caveolin-independent, 
negatively charged receptors. DC were incubated for 45 min with various inhibitors (A) 
sodium azide/2-deoxyglucose (1, 10 mM) (B) cytochalasin D (1, 10 µg/ml) (C) dextran 
sulphate (10, 50 µg/ml) (D) filipin III (1, 10 µg/ml) and (E) nystatin (10, 50 µg/ml) 
followed by incubation with AntpOVA at 100 µg/ml for 3 h and added to B3Z T cell 
hybridomas for 24 h. LacZ activity in B3Z T cells was assayed by total culture lysates with 
LacZ substrate CPRG and compared to controls with DC and B3Z cells without inhibitors 
(DC). The absorbance (560 nm) of culture wells was read after 4 h of incubation at 37oC. 
Experiments were performed in triplicate and values are presented as means plus SD with 
Student’s t tests and representative of 2 independent experiments. ***, p<0.001; **, 
p<0.01; *, p<0.05; ns, not significant. 
Endosomal and lysosomal processing.  
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Once AntpOVA is internalized it will be processed in one or more cellular compartments before 
peptides are loaded onto class I molecules for export onto the membrane.  To investigate this aspect we 
used several inhibitors that affect endosomal/lysosomal acidification, membrane recycling and 
transport. The possible role for endosomal processing using chloroquine and NH4Cl, which prevents 
acidification of endosomes and subsequent proteolysis was investigated[46-48]. After addition of 
chloroquine and NH4Cl, stimulation of B3Z was inhibited by 56±5%, suggesting that AntpOVA does 
present MHC class I specific peptide by initial degradation in the endosomal compartments (Figure 
5A). Similarly addition of Amiloride, which interferes with membrane recycling and 
macropinocytosis, also inhibited the stimulation of B3Z T cell hybridoma by 69±5% (Figure 5B)[49]. 
Monensin, is a sodium/proton (Na+/H+) ionophore which has multiple roles including interference with 
golgi transport, acidification of intracellular compartments and protein transfer from endosomes to 
lysosomes[50,51]. Consistant with the results observed with chloroquine/NH4Cl, the addition of 
Monensin led to a reduction in the stimulation of B3Z cells by 87±13% (Figure 5C). However, the 
greater inhibition by monensin compared to other inhibitors of the endolysosomal pathway would 
suggest additional inhibition of vesicular transport of loaded MHC class I from golgi to cell 
membrane. 
 
 
Figure 5. AntpOVA is endocytosed and processed in endosomes. DC were incubated 
for 45 min with various inhibitors (A) chloroquine/NH4Cl (20, 200 µM), (B) amiloride 
(0.6, 6 mM) and (C) monensin (100, 1000 µM) followed by incubation with AntpOVA at 
100 µg/ml for 3 h and added to B3Z T cell hybridomas for 24 h. LacZ activity in B3Z T 
cells was assayed by total culture lysates with LacZ substrate CPRG compared to controls 
with DC and B3Z cells without inhibitors (DC). The absorbance (560 nm) of culture wells 
was read after 4 h incubation at 37oC. Experiments were performed in triplicate and values 
are presented as means plus SD with Student’s t tests and representative of 2 independent 
experiments. ***, p<0.001; **, p<0.01. 
Proteolytic processing and peptide loading.   
13 
 
 
Brefeldin A, is an inhibitor that prevents the vesicle transport of newly synthesized MHC class I and 
class II molecules between ER and the Golgi apparatus[48]. Brefeldin A inhibited the presentation of 
class I peptide by DC to B3Z cells by 70±13% indicating the importance of newly synthesized class I 
for export of complexed peptide to the surface (Figure 6A). 
 
Figure 6. Proteolysis and peptide loading of AntpOVA. DC were incubated for 45 min 
with various inhibitors (A) brefeldin (1, 10 µg/ml), (B) lactacystin (1, 10 µM) and (C) 
protease inhibitor cocktail (1/10, 1/100 dilution) followed by incubation with AntpOVA at 
100 µg/ml for 3 h and added to B3Z T cell hybridomas for 24 h. Lacz activity in B3Z T 
cells was assayed by total culture lysates with LacZ substrate CPRG compared to controls 
with DC and B3Z cells without inhibitors (DC). The absorbance (560 nm) of culture wells 
was read after 4 h incubation at 37oC. Experiments were performed in triplicate and values 
are presented as means plus SD with Student’s t tests and representative of 2 independent 
experiments.  **, p<0.01; *, p<0.05; ns, not significant. 
Incubation of DC and AntpOVA in the presence of proteolytic inhibitors did not interfere with the 
presentation of antigen to B3Z cells confirming that the AntpOVA is not degraded extracellularly and 
then loaded onto MHC class I molecules on the surface (Figure 6C).  The addition of the proteasomal 
inhibitor lactacystin resulted in significant inhibition (55±5%) of antigen presentation (Figure 6B)[52]. 
Antigens can be further processed by enzymes present in the ER and Golgi compartments after initial 
proteasome processing.  Bestatin and a furin inhibitor also significantly impaired the presentation of 
antigen by DCs by 55±17% and 62±10% respectively (Figure 7A and B)[53-55]. 
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Figure 7. Proteolysis of Antp in endoplasmic reticulum and Golgi compartments. DC 
were incubated for 45min with various inhibitors (A) furin inhibitor (1, 10 µM) and (B) 
bestatin (1, 10 µM) followed by incubation with AntpOVA at 100 µg/ml for 3 h and added 
to B3Z T cell hybridomas for 24 h. LacZ activity in B3Z T cells was assayed by total 
culture lysates with LacZ substrate CPRG compared to controls with DC and B3Z cells 
without inhibitors (DC). The absorbance (560 nm) of culture wells was read after 4 h 
incubation at 37oC. Experiments were performed in triplicate and values are presented as 
means plus SD with Student’s t tests and representative of 2 independent experiments. **, 
p<0.01. 
In summary, the data indicates that for MHC class I presentation, at least 2 mechanisms of antigen 
presentation is available for AntpOVA. AntpOVA is taken up by endocytosis, digested in the 
endosomal compartment and peptides released into the cytoplasm or direct membrane translocation 
into the cytoplasm.  Subsequently AntpOVA or peptide fragments in the cytoplasm are cleaved further 
in the proteasome or ER and Golgi for loading onto empty class I molecules for export to the cell 
surface. 
 
MHC class II presentation.  
As shown in Figures 2 and 3, AntpOVA is processed in DC and presented by MHC class I as well 
as MHC class II to T cells.  To ascertain the mechanism of which AntpOVA is processed and 
presented by the classical MHC class II pathway we used various inhibitors as described above. 
Similar to that shown for MHC class I, NaN3/2-deoxyglucose and cytochalasin D inhibited the 
activation of OT-II cells by DC by 80% and 81%  at the highest concentration as measured by 
inhibition of intracellular IFN-secretionconfirming that uptake of AntpOVA is an energy dependent 
process involving endocytic process (Figure 8A, 8F). Class II presentation was also inhibited by 
NH4Cl/Chloroquine, inhibitors of endosomal and lysosomal acidification by 72% (Figure 8B). 
15 
 
 
 
Figure 8. AntpOVA specifically targets class II processing pathways. DCs were 
incubated for 45 minutes with inhibitors (A) sodium azide/2-deoxyglucose (B) 
NH4Cl/chloroquine (C) amiloride (D) monensin  (E) brefeldin and (F) cytochalasin D, 
followed by incubation with AntpOVA at 100 µg/ml for 24 h and added at a 1:10 ratio to 
OT-II purified T cells for 24 h. Intracellular IFN- expression was quantitated and used as 
a measure of T cell stimulation. DCs alone were used as a negative control and DCs pulsed 
with AntpOVA without any inhibitors at 100 µg/ml was used as an internal positive control 
which resulted in 20% of cells secreting IFN- (not shown). Data is shown as % 
intracellular IFN- expressing cells of gated CD3+ cells from triplicate wells (mean±SD) 
and representative of 2 independent experiments. 
Similar inhibition was obtained with amiloride (87%) and monensin (77%) (Figure 8C, 8D).  
Furthermore, brefeldin-A also inhibited presentation of MHC class II peptide by DC to OT-II cells by 
85% (Figure 8E). 
In summary, AntpOVA antigen is processed and presented by the classical class II pathway wherein 
it is taken up by endocytosis and degraded in the lysosomes prior to its loading to MHC class II 
molecules and export to the cell surface. 
 
Discussion 
Efficient generation of CD8+ T cells that recognize endogenously generated peptides presented by 
cell surface MHC class I molecules is crucial for the destruction of tumor cells or virus infected cells. 
These peptides are generated from endogenous proteins that are proteolytically degraded by 
proteasomes and transported to the ER via the TAP proteins to associate with MHC class I molecules 
and exported to the cell surface[5,56].  For generation of immune responses to an antigen, intracellular 
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delivery is the first step for access of antigens to the MHC class I and class II antigen processing and 
presentation pathways.  Exogeneous antigens are internalized by endocytosis, phagocytosis or 
pinocytosis and are transferred to the lysosomal compartments where the peptides from the degraded 
antigen is loaded onto MHC class II molecules and exported to the cell surface[57,58]. DC in 
particular are proficient in processing exogenous antigens for presentation by class I molecules via the 
cross-presentation pathway[58]. Most adjuvants have properties or are designed to access one or both 
of these pathways using a number of mechanisms such as the nature of the particulate  (microparticles, 
VLP, ISCOM)[59-62], having membrane fuseogenic properties (liposomes, ISCOM)[63,64] or cell 
surface receptor binding (mannan or recombinant antibody)[3,4,6,8].   
Membrane translocating peptides such as the peptide derived from the antennapedia homeodomain 
or HIV TAT protein have been used to shuttle proteins or peptides into the cytoplasm of antigen 
presenting cells[13,14,16,18-20,23,24,26,28,30,37,65].  In these studies synthetic peptides or 
recombinant peptide cytotoxic T lymphocyte (CTL) epitopes were linked in tandem with the 
membrane translocating sequence and they were capable of eliciting IFN-, CTL in mice and 
protection of mice from a tumor challenge. In addition immunogens consisting of multiple antigen 
peptides incorporating CD8 T cell epitopes chemically linked to penetratin or fusion peptides of 
penetratin with CD4 epitopes as well as CD4 and CD8 epitopes in tandem which were immunogenic 
and generated prophylactic and therapeutic protection in mice[15,21]. 
In addition to CD8 and CD4 T cell epitope membrane translocating peptides such as penetratin and 
TAT have been used to carry larger proteins such as ovalbumin and mucin 1 to antigen presenting cells 
either as chemically linked conjugates or recombinant fusion proteins[14,17,25,65,66].  There has only 
been one other study where the CPP from HIV TAT was chemically linked to ovalbumin with the aim 
of generating CTL to SIINFEKL and was also successful[17,21].  The mechanism, subcellular 
localization and membrane translocation of cell penetrating peptides vary dependent on cargo and cell 
type[12]. Therefore, in addition to the immunogenicity of peptide (eg. Tc or Th epitopes) or protein 
(eg. Protein antigens) cargo delivered to dendritic cells by penetratin, the effect on mechanism of 
antigen presentation is of interest. In the present study we have chemically linked penetratin to 
ovalbumin for the purpose of studying the OVA-specific Tc and Th immune responses to the conjugate 
in mice with or without DC and the mechanism of antigen presentation in DCs. 
Uptake of OVA with low carbohydrate (mannose) by C-type lectin receptors on DC is inefficient 
except at higher concentrations (>200 ug/ml) and uptake can be increased by enriching for higher 
glycoforms or by linkage to mannosylated dendrimers[31]. By utilization of a CPP, AntpOVA was 
more efficiently internalized than OVA by DCs as measured by intracellular staining with an anti-
OVA antibody.  At 100 g/ml 44±3% of the DCs internalized the AntpOVA within 5 min of 
incubation (Figure 1).  When incubated with DCs, AntpOVA was internalised, processed and 
SIINFEKL presented by class I molecules.  This was demonstrated using several methods – (i) 
stimulation of ovalbumin specific B3Z T cell hybrid, (ii) proliferation of T cells derived from OT-1 
mice and (iii) induction of OVA-specific CD8 response in vivo. In contrast to CPP fused in tandem to a 
Tc epitope peptide, AntpOVA conjugates also includes a Th epitope that can be translocated into the 
APC.  The presentation of the CD8 and CD4 epitopes by APC was investigated by incubating 
AntpOVA pulsed DC with OT-1 and monitoring the proliferative responses. It was demonstrated that 
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AntpOVA was processed and presented T cell epitopes by MHC class I and class II antigen processing 
pathways (Figures 2, 3)[21]. 
To determine whether AntpOVA conjugates were able to generate CD4 and CD8 responses in vivo 
as demonstrated in vitro, mice were immunized with AntpOVA alone or AntpOVA pulsed DCs and 
IFN- responses measured by ELISpot assays.  Splenocytes from mice immunized with AntpOVA and 
AntpOVA/DC responded by IFN- production on stimulation with OVA323-339 (OVACD4) as well as 
SIINFEKL peptides (Figure 2).  The splenocytes from mice immunized with OVA or OVA/DC 
yielded low levels of INF- only in response to OVACD4. 
Membrane translocating peptides such as penetratin and TAT have been shown to be taken up into 
cells in a receptor independent and energy independent manner[67]. More recently there have been 
increasing evidence to suggest that these peptides are taken up by receptor mediated endocytosis and 
not by a specific receptor but by negatively charged cell surface molecules such as heparin sulphate 
proteoglycans[68,69].  This interaction is solely due to an ionic interaction between the positively 
charged CPP and the negatively charged receptor.  The mechanism of antigen presentation of TAT- 
and penetratin-based peptide immunogens have been investigated however, there have been no 
mechanistic studies with penetratin-based whole proteins such as OVA[16,20,30,37]. 
From in vivo studies with whole ovalbumin protein linked to penetratin it was observed that 
ovalbumin epitopes access the MHC class I presentation pathway as well as the class II pathway 
indicating a possible involvement of an endocytic process (Figures 2, 3)[21].  This prompted us to 
investigate the mechanism of MHC class I and class II antigen presentation using the model systems 
described herein.  The entry of antigen into DC via an endocytic or pinocytosis process was confirmed 
by the reduction of stimulation of the B3Z cell line when cytochalasin D was used (Figure 4).  The 
inhibition was 56% of the maximum at 10 µg/ml in the B3Z assays. Inhibition of the presentation by 
the negatively charged dextran sulphate further confirms the involvement of a negatively charged receptor 
(Figure 4).  Chloroquine/NH4Cl, amiloride and monensin all inhibited antigen presentation indicating 
endosomal processing prior to presentation (Figure 5).  The inhibition with monensin was much higher 
(87%) compared to with chloroquine/NH4Cl (56%) and amiloride (69%) possibly due to the effect of 
monensin on the Golgi pH interfering with the trafficking of proteins. This observation together with 
the partial inhibition of uptake by cytochalasin D and azide/2-dG implies that an alternative energy 
independent mechanism of uptake and subsequent processing is operational. In the presence of the 
proteasomal inhibitor lactacystin presentation was partially (55 %) prevented indicating a proteosomal 
independent pathway (Figure 6).  The AntpOVA conjugates can also load class I molecules via a TAP 
independent mechanism as demonstrated using RMA-S cells and TAP-/- knockout mice (Figure 3).  
Interestingly, in contrast to synthetic CPP with Tc epitopes (AntpSIIN) where class I presentation is 
proteasome dependent, presentation of penetratin-OVA to T cells is proteasome dependent with a 
proteasomal independent mechanism as well[20]. However, both immunogens can load MHC class I 
molecules in a TAP independent manner. A furin inhibitor and bestatin also partially prevented antigen 
presentation (Figure 7) in contrast to the AntpSIIN fusion peptide where there was no effect[20].  
From the data it can be concluded that AntpOVA can enter the cytoplasm of cells via direct 
membrane translocation in an energy independent manner as well as an energy dependent endocytic 
process possibly via electrostatic interaction with negatively charged membrane lipids or 
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proteoglycans. At least two pathways of antigen processing for AntpOVA is available. AntpOVA is 
internalized by endocytosis, degraded in the endo-lysosomes and escapes into the cytosol for further 
proteolytic processing by the proteasome and loading class I in a TAP-dependent mechanism. 
Alternatively, AntpOVA can directly translocate into the cytoplasm followed by the proteolysis in the 
endoplasmic reticulum and Golgi compartments for loading into class I molecules in a TAP-
independent mode.   Our mechanistic data agrees with that of Lu et al[30] which demonstrates that 
TAT containing antigens can utilise alternative antigen presentation pathways bypassing the 
requirement for proteasomal processing and TAP dependence by proteolytic trimming in ER and Golgi 
compartments[30,70,71]. 
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